News
Videos
Conferences
Events
Resources
Subscribe

|Articles|April 20, 2017

Risk Factors and More: A Roundup of This Week's #CureFact Snippets

Author(s)CURE staff

Newsletter

Stay up to date on cancer updates, research and education

Related Content

If you are reading this, you, your family or loved one have most likely been affected by cancer: © stock.adobe.com.If you are reading this, you, your family or loved one have most likely been affected by cancer: © stock.adobe.com.

Debunking Hospice Misconceptions: A Focus on End-of-Life Care

ByDr. Joshua K. Sabari

December 18th 2025

Michelle Anderson-Benjamin

Hospice May Offer Patients With Cancer Some Peace, Comfort and Control

December 18th 2025

breast cancer

New Approach May Offer Stronger Treatment Effects in Metastatic Breast Cancer

December 18th 2025

Dan, a pancreatic cancer survivor

Stage 4 Pancreatic Cancer Survivor Shares Clinical Trial Path

BySpencer Feldman

December 18th 2025

The U.S. FDA has granted approval to Rybrevant Faspro, the first and only subcutaneous therapy for EGFR-mutated non-small cell lung cancer: © stock.adobe.com.

Rybrevant Faspro FDA-Approved as First Sub-Q Therapy for EGFR NSCLC

December 18th 2025

Trending on CURE

‘Full House’ Star Dave Coulier Talks Tongue Cancer Diagnosis

Rybrevant Faspro FDA-Approved as First Sub-Q Therapy for EGFR NSCLC

FDA Grants Regular Approval to Rubraca for Some With Prostate Cancer

Padcev/Keytruda Combo Extends Survival in Muscle-Invasive Bladder Cancer

GSK’227 Wins FDA Orphan Drug Designation in Small-Cell Lung Cancer